Quillaja saponins are a group of natural triterpenoid saponins mainly obtained from the bark, xylem, and branches of Quillaja saponaria Molina, an evergreen tree native to Chile and other parts of South America. Their molecular structure contains both hydrophilic sugar chains and a lipophilic triterpenoid core. This amphiphilic structure gives Quillaja saponins useful foaming, emulsifying, and solubilizing properties.

Beyond these traditional applications, Quillaja saponins have attracted significant attention in the biopharmaceutical industry. Certain fractions, particularly the highly purified QS-21, have strong immunostimulatory properties and can support both humoral and cellular immune responses. As a result, Quillaja saponin fractions have become important components in the development of modern vaccine adjuvants, including those used in recombinant protein, malaria, shingles, and other vaccine research and products.

However, producing high-purity saponin fractions is not a simple extraction process. The natural distribution of Quillaja resources is geographically limited, while crude extracts contain many saponin components with very similar physical and chemical properties. Compounds such as QS-7, QS-17, and QS-21 can therefore be difficult to separate and purify efficiently.

At the same time, pharmaceutical applications require reliable quality control and accurate analytical methods. The combination of raw-material limitations, complex molecular structures, difficult separation, and strict quality requirements has become an important technical challenge for the industry.

Although researchers worldwide have conducted extensive studies on the biological activity and adjuvant mechanisms of Quillaja saponins, industrial-scale preparation and purification technologies for pharmaceutical-grade saponins remain concentrated among a relatively small number of international companies and research organizations.

Against this background, this study examines global patent literature related to the preparation, extraction, purification, separation, and detection of saponins. The objective is to understand the development of the technology, identify major patent applicants, examine geographical distribution, and evaluate the major technical routes being developed around high-purity saponins and vaccine adjuvants.

1. Data Retrieval and Evaluation

The Google Patents global patent database was selected as the primary data source for this study. The database covers patent information from major jurisdictions and international systems, including the United States, China, the European Patent Office, the World Intellectual Property Organization, Japan, and Chile.

To focus on upstream saponin-processing technologies rather than downstream pharmaceutical formulations or general clinical applications, the search strategy combined product-related keywords with process-related terms.

The main keywords included:

• Quillaja saponin

• Quillaja saponaria

• Saponin

• QS-21

• QS-7

Process-related terms included:

• Preparation

• Extraction

• Purification

• Isolation

• Separation

• Detection

• Chromatography

The search period extended through December 31, 2025.

After the initial search, the data underwent several rounds of manual review. Patents that only mentioned saponins as background information but did not actually protect saponin-related technologies were removed. Patent documents belonging to the same technical invention but filed in different countries were grouped into a single patent family. Design patents and non-process utility models were also excluded.

Following this filtering and classification process, 2,415 core patent applications related to saponin preparation, extraction, purification, and detection were identified globally. After patent-family consolidation, the dataset contained 856 independent patent applications.

Because invention patent applications may remain unpublished for approximately 18 months after filing, patent data from 2024 and 2025 may not represent the complete number of applications. Therefore, these recent records should be regarded as a reference for identifying emerging technology trends rather than as a final count.

Figure 1. Annual patent application trend related to saponins.

2. Development Trend of Saponin Technology

2.1 Patent Application Trend Analysis

Changes in patent application numbers can provide a useful indication of technological activity and the development stage of an industry. Based on the analyzed data, global technology related to saponin preparation, extraction, purification, and detection can generally be divided into four stages.

2.1.1 Initial Exploration Period: Before the 1970s

Before the 1970s, patent activity in this field was relatively limited. Most available technologies relied on basic water extraction, alcohol precipitation, and simple organic-solvent extraction.

Because modern chromatography systems and advanced analytical instruments were not yet widely available, most products were crude saponin extracts with relatively low purity. Their main applications were industrial products such as detergents, foaming agents, and agricultural formulations.

At this stage, the potential value of individual saponin fractions for pharmaceutical and vaccine applications had not yet been fully recognized.

2.1.2 Technology Growth Period: 1980–1999

The development of modern biochemical separation technologies in the 1980s and 1990s significantly changed the industry.

High-performance liquid chromatography (HPLC), reversed-phase chromatography, and improved analytical methods made it possible to separate individual saponin fractions from complex Quillaja extracts.

A major milestone occurred in 1991, when researchers including Kensil and colleagues used reversed-phase HPLC to separate and identify numerous saponin components from Quillaja bark extracts such as Quil-A. Their research identified QS-21 as an important immunologically active component.

This discovery increased interest in high-purity saponins and encouraged pharmaceutical companies to develop more advanced separation and purification technologies.

2.1.3 Stable Development Period: 2000–2014

From 2000 to 2014, research increasingly moved toward industrial-scale production of pharmaceutical-grade saponins.

QS-21 and other fractions attracted particular attention because of their potential use in vaccine adjuvant systems. At the same time, researchers faced several practical problems, including saponin instability in aqueous environments and relatively low purification yields.

Patent activity during this period therefore expanded into areas such as membrane separation, multi-stage chromatography, counter-current separation, and LC-MS-based quality analysis.

2.1.4 New Growth and Green Innovation: 2015 to Present

Since 2015, saponin technology has entered another active development stage.

Growing interest in natural and environmentally friendly extraction methods, together with continued demand for modern vaccine adjuvants, has encouraged research into more efficient extraction and purification processes.

New patent applications increasingly cover technologies such as:

• Ultrasound-assisted extraction

• Microwave-assisted extraction

• Deep eutectic solvent (DES) extraction

• Advanced chromatography

• Trace-component detection

• High-resolution mass spectrometry

• Rapid quality identification

The focus is no longer limited to achieving higher purity. Improving extraction efficiency, reducing solvent use, increasing production yield, and establishing reliable quality-control methods have also become important development targets.

3. Geographical Distribution of Saponin Patents

3.1 Technology Origin

Patent origin can provide insight into where the major research and development activities are taking place.

According to the analyzed dataset, the United States represents the largest share of global saponin-related patent applications, accounting for 34.12% of the total.

China ranks second with 25.43%. Chinese research teams have increasingly applied modern separation technologies to natural-product extraction, including macroporous resin adsorption and high-speed counter-current chromatography.

Chile ranks third, with approximately 8.5% of applications. As the main natural resource region for Quillaja saponaria, Chilean companies have developed technologies covering the primary extraction and processing of Quillaja resources.

Companies such as Desert King International have established patent portfolios around large-scale extraction, decolorization, impurity removal, and preliminary purification.

The United Kingdom, Sweden, Japan, and several other countries also contribute to the global patent landscape.

The combined contribution of China and the United States is close to 60%, making these two countries major centers of technology development in this field.

Figure 2. Distribution of patent application origins related to Quillaja saponins.

3.2 Technology Target Locations

Patent target locations provide another perspective on where companies consider the market and intellectual-property environment to be strategically important.

China and the United States are the two largest patent receiving jurisdictions in the analyzed dataset. China accounts for approximately 31.25% of the target applications, reflecting the growing importance of its biopharmaceutical, vaccine, and health-product markets.

The European Patent Office accounts for approximately 9.12%, while the World Intellectual Property Organization and its PCT route account for approximately 8.37%.

The relatively high share of PCT filings indicates that companies are using international patent applications to establish protection across multiple markets.

Figure 3. Distribution of patent target locations related to Quillaja saponins.

4. Key Patent Applicants

Understanding the leading applicants helps identify the major technology developers and companies with strong patent portfolios.

Desert King International, based in Chile, is one of the most prominent companies in the Quillaja saponin industry. Its patent activities mainly focus on large-scale extraction, decolorization, impurity removal, and primary purification of natural saponin resources.

Large pharmaceutical companies such as GlaxoSmithKline (GSK) and Sanofi have developed a different type of patent portfolio. Their technologies place greater emphasis on high-purity pharmaceutical saponins, QS-21 purification, analytical testing, and adjuvant formulation.

Among the leading patent applicants, overseas pharmaceutical companies, natural-product companies, and government research organizations account for a significant proportion.

Chinese applicants are more commonly universities and research institutions, including institutes associated with the Chinese Academy of Sciences, Jiangnan University, Shenyang Pharmaceutical University, China Pharmaceutical University, and other research organizations.

This difference highlights an important development issue. China has produced a substantial number of patents in laboratory-scale extraction, separation, and analytical technologies, but the number of companies with mature industrial-scale production capabilities for pharmaceutical-grade Quillaja saponins remains relatively limited.

As a result, some promising laboratory technologies still need further development before they can be transferred into stable commercial production.

Figure 4. Ranking of major global applicants for Quillaja saponin patents.

5. Patent Type Analysis

The patent structure of this field is strongly concentrated in invention patents.

According to the analyzed data, invention patents, including applications and granted inventions, account for approximately 97.85% of the total. Utility models represent only about 2.04%, while design patents are almost absent.

Within the invention-patent category, approximately 54.12% are invention applications and 43.73% are granted inventions.

This distribution is understandable because saponin extraction and purification involve complex chemical separation, analytical testing, molecular modification, and process optimization.

Technologies such as chromatography conditions, extraction temperature, pressure, solvent selection, column flow rate, and impurity removal require substantial research and experimental validation.

Consequently, the intellectual-property barriers in this sector are considerably higher than those associated with simple equipment or structural improvements.

Figure 5. Patent type distribution related to Quillaja saponins.

6. Core Technical Elements of Saponin Patents

6.1 IPC Technology Distribution

The International Patent Classification (IPC) system provides a useful way to understand the main technical areas covered by global patent applications.

Three technology groups are particularly important.

Chromatographic Separation and Purification

IPC groups such as B01D15 and C07J63 cover technologies associated with chromatographic separation and purification of complex compounds.

These patents commonly address the enrichment and separation of target saponins from crude extracts containing polysaccharides, polyphenols, tannins, and other saponin components.

Common technologies include:

• Macroporous adsorption resins

• Reversed-phase silica chromatography

• Gel-permeation chromatography

• Multi-stage chromatographic purification

Vaccine Adjuvant Formulation

Another important area involves pharmaceutical compositions with immunostimulatory activity.

Patents in this area often examine how purified saponins such as QS-21 can be combined with cholesterol, phospholipids, or other components to form stable adjuvant systems.

This is particularly relevant because free saponins can have undesirable biological effects, while formulation into systems such as liposomes or immunostimulating complexes can improve their practical application.

Analytical Detection

The third major area involves chromatographic and mass-spectrometric analysis.

Modern quality control increasingly relies on technologies such as:

• HPLC-MS/MS

• UPLC

• HILIC

• High-resolution mass spectrometry

These analytical techniques help distinguish closely related saponin components, establish characteristic fingerprints, and improve batch-to-batch consistency.

Figure 6. IPC technology distribution related to Quillaja saponins.

7. Core Patent Routes of Major Global Applicants

7.1 Desert King International

The patent strategy of Desert King International primarily focuses on large-scale and efficient processing of natural Quillaja resources.

Its technology portfolio emphasizes crude extraction, decolorization, tannin removal, primary purification, and the preparation of intermediates suitable for further processing.

Earlier approaches focused on water-based extraction and large-volume purification. More recent technologies have explored intensified extraction methods and industrial chromatography.

The overall objective is to improve extraction efficiency, shorten processing time, increase saponin recovery, and provide a suitable intermediate for downstream high-purity purification.

This approach gives Desert King a strong position in the upstream part of the Quillaja saponin supply chain.

7.2 GSK: High-Purity Purification and Analytical Control

GSK's technology portfolio is more closely associated with high-purity saponins and vaccine adjuvant systems.

Its process technologies focus on advanced reversed-phase HPLC and controlled separation conditions for isolating high-value saponin components such as QS-21.

Another important area is quality control. Because QS-21 and related saponins contain structurally similar components, analytical methods must accurately identify individual components and monitor impurities.

Mass spectrometry and chromatographic fingerprinting therefore play an important role in establishing product consistency and quality standards.

Together, purification and analytical technologies form an important part of the technical barriers surrounding pharmaceutical-grade saponins.

8. Development Strategies for China's Saponin Industry

The global patent landscape shows that China has already become one of the major sources of saponin-related patent activity. However, there remains a noticeable gap between China and leading international companies in areas such as industrial-scale production, commercialization of core technologies, high-purity monomer manufacturing, and internationally recognized quality standards.

Several strategies may help improve the domestic industry.

8.1 Strengthen Industry-Academia-Research Cooperation

China has many universities and research institutions with valuable technologies for natural-product extraction and separation.

The next step should be to connect these laboratory technologies with commercial production.

Pharmaceutical companies, vaccine-adjuvant developers, and natural-product manufacturers can work with universities through joint research, technology licensing, patent transfer, and engineering centers.

The goal should be to transform laboratory-scale extraction and purification technologies into stable demonstration lines capable of producing pharmaceutical-grade saponins such as QS-21.

8.2 Build More Complete Quality Standards

Quality control is another important area for future development.

Because Quillaja saponins contain multiple closely related components, a single purity number may not be sufficient to describe product quality.

Future quality systems could combine chromatographic fingerprints, mass-spectrometry analysis, impurity limits, and biological activity measurements.

Developing recognized industry or national standards would help improve consistency between batches and support the wider commercialization of domestic saponin products.

8.3 Focus on Green and Differentiated Technologies

Traditional reversed-phase chromatography already has a substantial international patent foundation.

For new entrants, simply repeating existing technology routes may create both technical and intellectual-property challenges.

Future research can therefore focus more strongly on environmentally friendly and differentiated processes.

Potential directions include: